The Journal of Clinical Endocrinology & Metabolism Vol. 82, No. 11 3835-3841
Copyright © 1997 by The Endocrine Society
Three Novel Mutations and a De Novo Deletion Mutation of the DAX-1 Gene in Patients with X-Linked Adrenal Hypoplasia Congenita
Jun Nakae,
Shuji Abe,
Toshihiro Tajima,
Nozomi Shinohara,
Mari Murashita,
Yutaka Igarashi,
Satoshi Kusuda,
Junzou Suzuki and
Kenji Fujieda
Department of Pediatrics (J.N., S.A., T.T., N.S., M.M., K.F.),
Hokkaido University School of Medicine, Sapporo 060; Igarashi Pediatric
Clinic (Y.I.), Sendai; Department of Neonatology (S.K.), Osaka City
General Hospital, Osaka; Department of Pediatrics (J.S.), Fukushima
Prefectural Medical Collage, Fukushima, Japan
Address correspondence and requests for reprints to: Kenji Fujieda, Department of Pediatrics, Hokkaido University School of Medicine, North-15, West-7, Kitaku, Sapporo 060, Japan. E-mail:
ken-fuji{at}med.hokudai.ac.jp
 |
Abstract
|
|---|
The DAX-1 [DSS (dosage sensitive sex)-AHC critical region on the X,
gene 1] gene is responsible for X-linked adrenal hypoplasia congenita
(AHC). However, DAX-1 protein structure-function relationships are not
well understood. Identification of missense mutations may help to
reveal these relationships. We analyzed the DAX-1 gene from seven
patients in six kindreds with X-linked AHC and identified one
frameshift mutation, two missense mutations, and three deletion
mutations. Case 1 had a 388delAG frameshift mutation, inducing a
premature stop codon at position 70. Case 2 had a missense mutation,
Lys382Asn, which encodes an asparagine (Asn) for lysine (Lys) at
position 382. Sibling cases of 3-1 and 3-2 had a missense mutation of
Trp291Cys, which encodes a substitution of cysteine (Cys) for
tryptophan (Try) at position 291. The tryptophan (Trp) at position 291
and lysine (Lys) at position 382 in human DAX-1 protein are highly
conserved among other related orphan nuclear receptor superfamily
members. Cases 4, 5, and 6 showed deletion mutation. In case 6, a
de novo deletion mutation was revealed by both southern
hybridization and polymerase chain reaction (PCR) of a GGAA
tetranucleotide tandem repeat. These findings suggest that: 1) Trp at
position 291 and Lys at position 382, located in the C-terminal
presumptive ligand binding domain, are important to the functional role
of the DAX-1 protein in adrenal embryogenesis and/or in
hypothalamic-pituitary activity; and 2) molecular analysis of the DAX-1
gene may help genetic counseling, even in cases with deletion mutation,
because a detection of de novo deletion may exclude another
affected or carrier child.
 |
Introduction
|
|---|
X-LINKED ADRENAL hypoplasia congenita (AHC)
is a rare congenital adrenal disorder characterized by severe adrenal
insufficiency. This disorder often manifests salt-losing adrenal
insufficiency during the neonatal period and requires intensive medical
care (1, 2, 3, 4, 5, 6, 7, 8, 9, 10). The DAX-1 [DSS (dosage-sensitive sex)-AHC critical
region on the X, gene 1] gene was identified as responsible for both
X-linked AHC and hypogonadotropic hypogonadism (HH) (11, 12). The DAX-1
gene encodes the presumptive transcription factor and is classified as
an orphan nuclear receptor (11, 12). The DAX-1 protein is a 470 amino
acid polypeptide, with its coding sequence split by a single intron of
about 3 kb. The C-terminal half of the protein has high homology with
the ligand-binding domain (domain E) of the nuclear hormone receptor
gene superfamily, especially with the E domain of the retinoid X
receptor (RXR) and the orphan receptor (EAR-2, seven-up, COUP, ARP-1)
subfamilies. The N-terminal portion contains 4 incomplete repeats of a
new structural motif encoding a DNA-binding function, and the DAX-1
protein is reported to bind retinoic acid (RA) responsive elements and
downregulate RA receptor-mediated transcriptional activation (11). The
C-terminal half domain of the DAX-1 protein is similar to the
ligand-binding domain (E-domain) of the nuclear hormone receptor
superfamily (11, 13, 14). The DAX-1 gene was expressed in adult testis
and adult adrenal tissue and has an important role in development of
these tissues (11). However, the structure and function of the DAX-1
protein remains to be demonstrated. Molecular analysis of the DAX-1
gene in patients with X-linked AHC gives insight into the structure and
function of the DAX-1 protein. Over 20 different mutations have now
been identified (12, 15, 16, 17, 18, 19, 20, 21). No relationship between the onset of
disorder and the site of mutation has been demonstrated. Furthermore,
the C-terminus of this protein plays an important role in its
function.
In the present study, we analyzed the DAX-1 gene in seven patients from
six kindreds and identified one novel frameshift mutation, two novel
missense mutations, and a de novo deletion mutation of the
DAX-1 gene. We discussed the functional significance of the mutated
amino acids.
 |
Subjects and Methods
|
|---|
Subjects (Tables 1
and 2
)
Clinical and laboratory findings are shown in Tables 1
and 2
.
The onsets of the disorder in all cases, except cases 3-1 and 3-2, were
during their neonatal period. Cases 3-1 and 3-2 manifested adrenal
insufficiency at the ages of 2 yr and 3 yr, respectively. The initial
symptoms of all cases except cases 3-1 and 3-2 were failure to thrive,
generalized pigmentation, poor feeding, or vomiting. The initial
symptom of cases 3-1 and 3-2 was only generalized pigmentation. In
addition, cases 4 and 5 had also mental retardation. Laboratory
findings of all cases at diagnosis showed hyponatremia, hyperkalemia,
increased levels of plasma ACTH and plasma renin activity (PRA), or
impaired serum cortisol response to the administration of ACTH.
However, in cases 3-1 and 3-2, levels of serum potassium and plasma
ACTH were modestly elevated. Case 1 is now 26 yr old. He is 179.3 cm
tall (+1.5 SD for the mean of normal Japanese male) with
67.5 kg of weight (+0.5 SD for the mean of normal Japanese
male). His external genitalia is Tanner stage 1 and bone age estimated
by the Greulich and Pyle method is 14 yr old. Case 4 is now 15 yr old
with Tanner stage 1 genitalia. His serum testosterone level is less
than 5.0 ng/dL. However, the administration of human chorionic
gonadotropin (hCG) at a dose of 4000 IU for 4 days increased serum
testosterone to 186.1 ng/dL. In both cases, serum LH and FSH values
were not measured. Other cases are in the prepubertal age. Informed
consent was obtained from each family. This study was approved by the
Regional Committee for Medical Research Ethics.
Polymerase chain reaction (PCR)-direct sequencing of the DAX-1 gene
and sequence-specific oligonucleotide hybridization
Genomic DNA was isolated from peripheral lymphocytes. PCR was
performed using primer pairs specific for the DAX-1 gene. PCR
amplification was performed as described previously (18). Direct
sequencing of amplified PCR products was determined from both strands
using an automated sequencer (ABI PRISM 310 Genetic Analyzer, Applied
Biosystems, Foster City, CA). The mutations detected were confirmed in
mothers and other family members by sequencing their genomic DNA
partially. Furthermore, to confirm mutations detected,
sequence-specific oligonucleotide hybridization was performed. In
brief, genomic DNA from each case was amplified by PCR using primer 1
and 2 (18) for the 388delAG frameshift mutation, primer 7 and 10 (18)
for the Lys382Asn mutation, or primer 7 and 8 (18) for the Trp291Cys
mutation. After amplification, each PCR product was electrophoresed in
2% agarose gel and blotted onto nitrocellulose filter. Each filter was
hybridized in solution containing 6 x SSC, 5 x Denhardts
solution, 0.05% sodium pyrophosphate, 0.5% SDS, and 100 µg/mL
salmon sperm DNA with sequence-specific 32P-end labeled
21-mer oligonucleotide at 42C for 20 h. Each oligonucleotide was
labeled with 32P-ATP as described elsewhere (22). For the
388delAG frameshift mutation, wild and mutant type oligonucleotides
were 5'-GTG GGC AGA GAG GGG CTG CTG-3' (nucleotides 379-399) (388Wild)
and 5'-GTG GGC AGA GGG GCT GCT GGG-3' (388delAG), respectively. For the
Lys382Asn mutation, wild and mutant type oligonucleotides were 5'-GCC
TAC CTC AAG GGG ACC GTG-3' (nucleotides 13691389) (Lys382) and 5'-GCC
TAC CTC AAT GGG ACC GTG-3' (Asn382), respectively. For the Trp291Cys
mutation, wild and mutant type oligonucleotides were 5'-CGC AAC TGC TGG
GCG TCC CTG-3' (nucleotides 1096-1117) (Trp291) and 5'-CGC AAC TGC TGC
GCG TCC CTG-3' (Cys291), respectively. The positions of all
oligonucleotides were in accordance with those previously described
(11). After hybridization, each filter was washed at room temperature
for 10 min 3 times, and at 6570C for 5 min once in solution
containing 6 x SSC and 0.05% sodium pyrophosphate and exposed to
autoradiography film for 12 h at -80C with an intensifying
screen.
Southern hybridization of the DAX-1 gene
In each case where DAX-1 gene could not be amplified by PCR,
Southern blotting was performed as described elsewhere (22). In brief,
genomic DNA (10 µg) was digested with EcoRI, electrophoresed in 0.8%
agarose gel, and blotted onto a nitrocellulose filter. The filters were
probed with the DAX-1 cDNA and human insulin receptor (IR)
complementary DNA (cDNA). The DAX-1 cDNA (nucleotides 889-1708) was
obtained by reverse transcriptase-PCR using the DAX-1 gene-specific
primer pairs [primer 7 and 12 (18)] from messenger RNA of human
adrenal adenoma in a patient with Cushing syndrome. The human insulin
receptor (IR) cDNA (p13-1), which was about 1.0 kb pairs of the
5'-portion of human IR cDNA cloned into EcoRI site of a pUC 12 vector
was provided by I. Smith (Genentech, Inc., San Francisco, CA).
Intensities of bands detected were measured by NIH Image (NIH computer
center shareware).
PCR of a GGAA tetra-nucleotide tandem repeat
The DAX-1 gene has two potentially polymorphic short tandem
repeats (17). One of them, the GGAA tetra-nucleotide tandem repeat
[(GGAA)6GGAAA(GGAA)5GGAAAGGAAGGAAA(GGAA)10],
is located in the promoter region of the DAX-1 gene (nucleotides -1492
~ -1395) (17). To confirm double dosage of the DAX-1 gene from the
mother of case 6, we performed PCR of the GGAA tetra-nucleotide tandem
repeat from family members of case 6, normal male and female controls.
PCR was performed with slight modification in accordance with the
procedure previously described (17). In brief, the 50-µL PCR reaction
contained 500 ng genomic DNA, primer 15 and 3140 (50 pmol/L each) (17),
20 nmol/L deoxynucleotide triphosphate, 0.1 µL
-32P-deoxycytidine triphosphate (300 Ci/mmol and 10
mCi/mL; Amersham, Arlington Heights, IL), two units of Taq DNA
polymerase (Perkin Elmer, Foster City, CA) and the PCR buffer contained
10 mmol/L Tris-HCl (pH 8.8), 50 mmol/L KCl, 1.5 mmol/L
MgCl2, and 0.1% gelatin. The PCR condition for
amplification of this fragment was 1.0 min denaturation at 94C, 1.0 min
annealing at 55C, and 1.0 min extension at 72C for 32 cycles. A 3-µL
aliquot of the PCR reaction was mixed with 9 µL of the stop solution
(95% formamide, 10 mmol/L EDTA, pH 8.0, 0.01% xylene cyanol) and
denatured for 5 min at 94C. Then, 4-µL aliquots of the mixtures were
loaded on 6% polyacrilamide/8.3 mol/L urea gel. Electrophoresis was
performed at 1200 volts for 5 h. The gel was dried before being
exposed to autoradiography film for 2 h at -80C with an
intensifying screen.
 |
Results
|
|---|
PCR-direct sequencing of the DAX-1 gene
In 4 patients from 3 kindreds, one frameshift mutation (388delAG)
and two missense mutations (Lys382Asn and Trp291Cys) were identified.
In case 1, the 388delAG mutation had a deletion of two bases (AG) at
nucleotides 388 and 389, inducing a frameshift and a premature stop
codon at position 70 (Fig. 1A
). In case
2, a missense mutation, Lys382Asn, was due to a transversion of G to T
at nucleotide 1380, encoding an asparagine (Asn) for lysine (Lys) at
position 382 (Fig. 2A
). The mother of
case 2 was heterozygous for the Lys382Asn mutation. The sister of case
2 did not have any mutation (data not shown). Sibling cases of 3-1 and
3-2 had missense mutations of Trp291Cys, due to a transversion of G to
C at nucleotide 1107, which encodes a substitution of cysteine (Cys)
for tryptophan (Try) at position 291 (Fig. 3A
). Their mother was heterozygote for
the mutation (data not shown). The Lys382Asn and Trp291Cys mutations
were not detected in 50 normal controls. Sequence-specific
oligonucleotide hybridization allowed the demonstration of the
cosegregation of these mutations with X-linked AHC (Figs. 1B
, 2B
, 3B
).

View larger version (15K):
[in this window]
[in a new window]
|
Figure 1. A, Partial nucleotide sequence of the DAX-1 gene
of case 1. After amplification using primers 1 and 2 (18) and
purification by electrophoresis on Nusieve low melting agarose gel (FMC
BioProducts, Rockland, ME), the PCR-amplified product was directly
sequenced, as described in Subjects and Methods. B,
Sequence-specific oligonucleotide hybridization of case 1 (lane 1),
normal male (lane 2), and normal female (lane 3). PCR of genomic DNA
from each case and hybridization with wild type or mutant type
oligonucleotide were performed, as described in Subjects and
Methods. For the 388del AG frameshift mutation, wild type and
mutant type oligonucleotides were 5'-GTG GGC AGA GAG GGG CTG CTG-3'
(nucleotides 379-399) (388Wild) and 5'-GTG GGC AGA GGG GCT GCT GGG-3'
(388delAG), respectively.
|
|

View larger version (20K):
[in this window]
[in a new window]
|
Figure 2. A, Partial nucleotide sequence of the DAX-1 gene
of case 2. After amplification using primers 7 and 10 (18) and
purification by electrophoresis on Nusieve low melting agarose gel, the
PCR-amplified product was directly sequenced, as described in
Subjects and Methods. B, Sequence-specific oligonucleotide
hybridization of case 2 (lane 1), his mother (lane 2), and sister (lane
3). PCR of genomic DNA from each case and hybridization with wild type
or mutant type oligonucleotide were performed, as described in
Subjects and Methods. For the Lys382Asn mutation, wild type
and mutant type oligonucleotides were 5'-GCC TAC CTC AAG GGG ACC GTG-3'
(nucleotides 13691389) (Lys382) and 5'-GCC TAC CTC AAT GGG ACC GTG-3'
(Asn382), respectively.
|
|

View larger version (21K):
[in this window]
[in a new window]
|
Figure 3. A, Partial nucleotide sequence of the DAX-1 gene
of case 3-1. After amplification using primers 7 and 8 (18) and
purification by electrophoresis on Nusieve low melting agarose gel, the
PCR-amplified product was directly sequenced, as described in
Subjects and Methods. B, Sequence-specific oligonucleotide
hybridization of case 3-1 (lane 1), case 3-2 (lane 2), his father (lane
3), mother (lane 4) and sister (lane 5). PCR of genomic DNA from each
case and hybridization with wild type or mutant type oligonucleotide
were performed, as described in Subjects and Methods. For
the Trp291Cys mutation, wild type and mutant type oligonucleotides were
5'-CGC AAC TGC TGG GCG TCC CTG-3' (nucleotides 1096-1117) (Trp291) and
5'-CGC AAC TGC TGC GCG TCC CTG-3' (Cys291), respectively.
|
|
Detection of de novo deletion of the DAX-1 gene.
In three cases of patients 4, 5, and 6, the DAX-1 gene could not
be amplified by PCR. To identify a deletion mutation of the DAX-1 gene
in cases of 4, 5, and 6, we performed a Southern hybridization.
Deletion mutations of the DAX-1 gene were detected in these cases (Fig. 4A
, lane 1, 5, and 7). The mother of case
6 had double dosage of the DAX-1 gene of the proband. Furthermore,
Southern hybridization of the same filter probed with human IR cDNA
(p13-1) demonstrated the same intensity of the human IR gene in the
proband and his mother (Fig. 4B
). Ratios of intensity of bands of the
DAX-1 and human IR genes measured by NIH Image were 1.30 in the mother
and 0.70 in the father, respectively. If the mother of case 6 is a
carrier of deletion mutation of the DAX-1 gene, she should have the
same dosage of the DAX-1 gene as the father of case 6. Furthermore, PCR
of the GGAA tetra-nucleotide tandem repeat from family members of case
6 detected no band in case 6, two bands in the mother, and one band in
younger brother of case 6 (Fig. 5
, lane
4, 6, and 7, respectively). These data suggest that deletion mutation
of the DAX-1 gene in case 6 occurred in de novo, indicating
that his mother is not a carrier of this disorder.

View larger version (64K):
[in this window]
[in a new window]
|
Figure 4. A, Southern hybridization of the DAX-1 gene from
case 4-6. After being digested with restriction enzyme, EcoRI, genomic
DNA (10 µg) was electrophoresed on 0.8% agarose gel and Southern
hybridization was performed as described in Subjects and
Methods. The filter was probed with the DAX-1 cDNA. Lanes 1, 2, 3,
4, 5, 6, 7, 8, and 9 represent case 4, normal female, normal male,
father of case 5, case 5, mother of case 5, case 6, father of case 6,
and mother of case 6, respectively. B, Southern hybridization of human
insulin receptor (IR) gene from case 6 and his parents. Genomic DNA was
isolated from peripheral lymphocytes of case 6 and his parents. After
being digested with restriction enzyme, EcoRI, genomic DNA was
electrophoresed on 0.8% agarose gel and Southern hybridization was
performed as described in Subjects and Methods. The filter
was probed with the human IR cDNA. Lanes 1, 2, and 3 represent case 6,
his father, and mother, respectively.
|
|

View larger version (52K):
[in this window]
[in a new window]
|
Figure 5. PCR of a GGAA tetra-nucleotide tandem repeat from
family members of case 6, normal male, and female controls. PCR was
performed using primers 15 and 3140 (17) as described in Subjects
and Methods. Lane 13 represent normal males. Lanes 4, 5, 6, 7
represent case 6, father of case 6, mother of case 6, and younger
brother of case 6, respectively. Lanes 810 represent normal female.
|
|
 |
Discussion
|
|---|
In the present study, we identified three novel mutations,
including one frameshift mutation and two missense mutations, and a
de novo deletion of the DAX-1 gene in patients with X-linked
AHC. The 388delAG mutation induces a premature stop codon at position
70, resulting in either a truncated DAX-1 protein or an instability of
the DAX-1 mRNA. The detection of a missense mutation could be important
for understanding the relationships between the structure and function
of the DAX-1 protein. However, only a few missense mutations have been
reported (12, 19). We identified two novel missense mutations of the
Trp291Cys and Lys382Asn. Interestingly, clinical courses of cases 3-1
and 3-2 with a mutation of Trp291Cys are less typical for X-linked AHC
than those of other cases. The biological significance of these
mutations cannot be defined until expression studies and studies using
mouse models of altered DAX-1 expression are performed. However, DAX-1
was recently reported to inhibit steroidogenic factor 1 (SF-1)
transcriptional activity. Two naturally occurring missense mutations
(Arg267Pro and
Va1269) in the DAX-1 gene failed to inhibit SF-1
transcriptional activity in the expression study (23). These studies
may reveal the biological significance of the Trp291Cys and Lys382Asn
mutations we identified. Nevertheless, the DAX-1 protein has the
highest homology between the RXR and orphan receptor subfamilies (11).
Tryptophan at position 291 and lysine at position 382 of the human
DAX-1 protein are highly conserved among other orphan nuclear receptor
superfamilies, especially in the mouse DAX-1 protein (11, 24). Thus, it
is conceivable that these amino acids might play an important role in
the biological actions of DAX-1 protein. Most missense mutations of the
DAX-1 gene previously reported are located only in the C-terminal
presumptive ligand-binding domain. Furthermore, all mutations
located in the N-terminal half domain are frameshift or nonsense
mutations. No missense mutations were detected in the N-terminal
presumptive DNA-binding domain. The Lys382Asn and the Trp291Cys
mutations are located in the C-terminal presumptive ligand binding
(Fig. 6
). We reported previously that
truncation at the C-terminus of the DAX-1 protein impairs its
biological actions. Taken together, these findings could strongly
suggest that the C-terminal half of the DAX-1 protein may be more
important than the N-terminal half for DAX-1 protein function.
Alternatively, other possibilities may be present; the N-terminal
domain may be critical for some other function of DAX-1, such that a
different phenotype, isolated HH perhaps, results from missense
mutations in the N-terminal domain.

View larger version (24K):
[in this window]
[in a new window]
|
Figure 6. Mutations in the DAX-1 gene currently identified.
Mutations underlined were discussed in the present study. Other
mutations were cited from references (12, 1521). Arrows
indicate positions of localization of the premature stop codon caused
by nonsense or frameshift mutations, missense or deletion mutations.
|
|
A de novo deletion mutation is a rare event, and a de
novo deletion of the DAX-1 gene has not previously been reported.
Identification of a case with a de novo deletion mutation of
the DAX-1 gene reinforces the importance of molecular analysis of the
patients mother for genetic counseling. The implication is that one
would argue that this is a new genetic event and that the mother of
case 6 may be told that she will not have another affected or carrier
child. Although we cannot totally exclude the possibility that gonadal
mosaicism does exist for DAX-1 mutations, patients with X-linked AHC
due to gonadal mosaicism have not been reported. Indeed, the evidence
that a younger brother of case 6 has no deletion of the DAX-1 gene may
exclude the possibility of gonadal mosaicism in this family.
It is interesting to note that cases 4 and 5 with deletion mutations of
the DAX-1 gene are mentally retarded. In the present study, we did not
study the extent of the deletion in their genomic DNA. However, it has
been recently reported that a gene responsible for X-linked mental
retardation (MR) is located near AHC on the X chromosome (25, 26, 27, 28).
Thus, it is conceivable that these patients also have a deletion
encompassing a gene responsible for X-linked mental retardation.
Detailed mapping of the deletions in these patients might allow more
refined localization of the MR locus, such as has been recently carried
by Billuart et al. (28).
In conclusion, we identified three novel mutations, including one
frameshift, two missense mutations, and a de novo deletion
of the DAX-1 gene. Tryptophan at position 291 and lysine at position
382, located in the C-terminal presumptive ligand binding domain, may
play an important role for the biological actions of the DAX-1 protein,
such as in adrenal embryogenesis and/or in hypothalamic-pituitary
activity. The identification of a de novo deletion of the
DAX-1 gene reinforces the importance of genetic counseling with family
members of a patient with X-linked AHC and HH. A detection of de
novo deletion may exclude another affected or carrier child.
Received March 7, 1997.
Revised July 9, 1997.
Accepted July 15, 1997.
 |
References
|
|---|
-
Migeon CJ, Donohoue P. 1994 Adrenal disorders.
In: Kappy MS, Blizzard RM, Migeon C, et al eds.
Wilkinsthe diagnosis and treatment of endocrine disorders in
childhood and adolescence. 4th ed. Springfield: Thomas; 717856.
-
Sikl H. 1948 Addisons disease due to congenital
hypoplasia of the adrenals in an infant aged 33 days. J Path Bact. 60:323324.[CrossRef][Medline]
-
Briggs JN, Goodwin JF, Wilson A. 1951 Addisons
disease occurring in two brothers. Br Med J. i:115117.
-
Harlem OK, Myhre E. 1957 Congenital adrenal
hypoplasia: report of a case with the characteristic clinical features
of desadrenocorticism and autopsy finding of extreme hypoplasia of the
adrenal glands. Amer J Dis Child. 94:696701.
-
Mitchell RG, Rhaney K. 1959 Congenital adrenal
hypoplasia in siblings. Lancet. i:488492.
-
Meakin JW, Nelson DH, Thorn GW. 1959 Addisons
disease in two brothers. J Clin Endocrinol Metab. 19:726731.
-
Boyd JF, MacDonald AM. 1960 Adrenal cortical
hypoplasia in siblings. Arch Dis Child. 35:561568.[Free Full Text]
-
DAlbora JB, Martin MM. 1966 Addisons disease
in childhood. Report of two cases. Amer J Dis Child. 11:208214.
-
Wakefield MA, Brown RS. 1981 X-linked congenital
Addisons disease. Arch Dis Child. 56:7374.[Abstract/Free Full Text]
-
Peterson KE, Bille T, Jacobsen BB, Iversen T. 1982 X-linked congenital adrenal hypoplasia. A study of five generations of
a Greenlandic family. Acta Paediatr Scand. 71:947951.[Medline]
-
Zanaria E, Muscatelli F, Bardini B, et al. 1994 An
unusual member of the nuclear hormone receptor superfamily responsible
for X-linked adrenal hypoplasia cingenita. Nature. 372:635641.[CrossRef][Medline]
-
Muscatelli F, Strom TM, Walker AP, et al. 1994 Mutations in the DAX-1 gene give rise to both X-linked adrenal
hypoplasia congenita and hypogonadotropic hypogonadism. Nature. 372:672676.[CrossRef][Medline]
-
Mangelsdorf DJ, Evans RM. 1995 The RXR heterodimers
and orphan receptors. Cell. 83:841850.[CrossRef][Medline]
-
Kastner P, Mark M, Chambon P. 1995 Nonsteroid
nuclear receptors: what are genetic studies telling us about their role
in real life? Cell. 83:859869.[CrossRef][Medline]
-
Yanase T, Takayanagi R, Oba K, Nishi Y, Ohe K, Nawata
H. 1996 New mutations of DAX-1 genes in two Japanese patients with
X-linked congenital adrenal hypoplasia and hypogonadotropic
hypogonadism. J Clin Endocrinol Metab. 81:530535.[Abstract]
-
Habiby RL, Boepple P, Nachtigall L, Sluss PM, Crowley
WF, Jameson JL. 1996 Adrenal hypoplasia congenita with
hypogonadotropic hypogonadism. Evidence that DAX-1 mutations lead to
combined hypothalamic and pituitary defects in gonadotroph. J Clin
Invest. 98:10551062.[Medline]
-
Guo W, Burris TP, Zhang YH, et al. 1996 Genomic
sequence of the DAX-1 gene: an orphan nuclear receptor responsible for
X-linked adrenal hypoplasia congenita and hypogonadotropic
hypogonadism. J Clin Endocrinol Metab. 81:24812486.[Abstract]
-
Nakae J, Tajima T, Kusuda S, et al. 1996 Truncation
at the C-terminus of the DAX-1 protein impairs its biological actions
in patients with X-linked adrenal hypoplasia congenita. J Clin
Endocrinol Metab. 81:36803685.[Abstract]
-
Schwartz M, Blichfeldt S, Muller J. 1997 X-linked
adrenal hypoplasia in a large Greenlandic family. Detection of a
missense mutation (N440I) in the DAX-1 gene; implication for genetic
counselling and carrier diagnosis. Hum Genet. 99:8387.[CrossRef][Medline]
-
Guo W, Mason JS, Stone Jr CG, et al. 1995 Diagnosis
of X-linked adrenal hypoplasia congenita by mutation analysis of the
DAX-1 gene. JAMA. 274:324330.[Abstract/Free Full Text]
-
Takahashi T, Shoji Yu, Shoji Ya, Haraguchi N, Takahashi
I, Takada G. 1997 Active hypothalamic-pituitary-gonadal axis in an
infant with X-linked adrenal hypoplasia congenita. J Pediatr. 130:485488.[CrossRef][Medline]
-
Maniatis T, Fritsch EF, Sambrook J. 1982 Molecular
cloning: a laboratory manual. Cold Spring Harbor: Cold Spring Harbor
Laboratory.
-
Ito M, Yu R, Jameson JL. 1997 DAX-1 inhibits
SF-1-mediated transactivation via a carboxy-terminal domain that is
deleted in adrenal hypoplasia congenita. Mol Cell Biol. 17:14761483.[Abstract]
-
Bae DS, Schaefer ML, Partan BW, Muglia L. 1996 Characterization of the mouse DAX-1 gene reveals evolutionary
conservation of a unique amino-terminal motif and widespread expression
in mouse tissue. Endocrinology. 137:39213927.[Abstract]
-
Neri G, Chiurazzi P, Arena JF, Lubs HA. 1994 XLMR
genes: update 1994. Am J Med Genet. 51:542549.[CrossRef][Medline]
-
Fries MH, Lebo RV, Schonberg SA, et al. 1993 Mental
retardation locus in Xp21 chromosome microdeletion. Am J Med
Genet. 46:363368.[CrossRef][Medline]
-
Kozak L, Chiurazzi P, Genuardi M, Pomponi MG, Zollino M,
Neri G. 1993 Mapping of a gene for non-specific X-linked mental
retardation: evidence for linkage to chromosomal region Xp21.1-Xp22.3. J Med Genet. 30:866869.[Abstract/Free Full Text]
-
Billuart P, Vinet MC, Portes V, et al. 1996 Identification by STS PCR screening of a microdeletion in Xp21.3-22.1
associated with non-specific mental retardation. Hum Mol Genet. 5:977979.[Abstract/Free Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
L. Lin, W.-X. Gu, G. Ozisik, W. S. To, C. J. Owen, J. L. Jameson, and J. C. Achermann
Analysis of DAX1 (NR0B1) and Steroidogenic Factor-1 (NR5A1) in Children and Adults with Primary Adrenal Failure: Ten Years' Experience
J. Clin. Endocrinol. Metab.,
August 1, 2006;
91(8):
3048 - 3054.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Ozisik, G. Mantovani, J. C. Achermann, L. Persani, A. Spada, J. Weiss, P. Beck-Peccoz, and J. L. Jameson
An Alternate Translation Initiation Site Circumvents an Amino-Terminal DAX1 Nonsense Mutation Leading to a Mild Form of X-Linked Adrenal Hypoplasia Congenita
J. Clin. Endocrinol. Metab.,
January 1, 2003;
88(1):
417 - 423.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Domenice, A. C. Latronico, V. N. Brito, I. J. P. Arnhold, F. Kok, and B. B. Mendonca
Adrenocorticotropin-Dependent Precocious Puberty of Testicular Origin in a Boy with X-Linked Adrenal Hypoplasia Congenita Due to a Novel Mutation in the DAX1 Gene
J. Clin. Endocrinol. Metab.,
September 1, 2001;
86(9):
4068 - 4071.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C. Achermann, M. Ito, B. L. Silverman, R. L. Habiby, S. Pang, A. Rosler, and J. L. Jameson
Missense Mutations Cluster within the Carboxyl-Terminal Region of DAX-1 and Impair Transcriptional Repression
J. Clin. Endocrinol. Metab.,
July 1, 2001;
86(7):
3171 - 3175.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. J. Tremblay and R. S. Viger
Nuclear Receptor Dax-1 Represses the Transcriptional Cooperation Between GATA-4 and SF-1 in Sertoli Cells
Biol Reprod,
April 1, 2001;
64(4):
1191 - 1199.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
Mutational Analysis of DAX1 in Patients with Hypogonadotropic Hypogonadism or Pubertal Delay
J. Clin. Endocrinol. Metab.,
December 1, 1999;
84(12):
4497 - 4500.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
P. Caron, S. Imbeaud, A. Bennet, M. Plantavid, G. Camerino, and P. Rochiccioli
Combined Hypothalamic-Pituitary-Gonadal Defect in a Hypogonadic Man with a Novel Mutation in the DAX-1 Gene
J. Clin. Endocrinol. Metab.,
October 1, 1999;
84(10):
3563 - 3569.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. P. Merke, T. Tajima, J. Baron, and G. B. Cutler
Hypogonadotropic Hypogonadism in a Female Caused by an X-Linked Recessive Mutation in the DAX1 Gene
N. Engl. J. Med.,
April 22, 1999;
340(16):
1248 - 1252.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. T. Reutens, J. C. Achermann, M. Ito, M. Ito, W.-X. Gu, R. L. Habiby, P. A. Donohoue, S. Pang, P. C. Hindmarsh, and J. L. Jameson
Clinical and Functional Effects of Mutations in the DAX-1 Gene in Patients with Adrenal Hypoplasia Congenita
J. Clin. Endocrinol. Metab.,
February 1, 1999;
84(2):
504 - 511.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
S. B. Seminara, F. J. Hayes, and W. F. Crowley Jr.
Gonadotropin-Releasing Hormone Deficiency in the Human (Idiopathic Hypogonadotropic Hypogonadism and Kallmann's Syndrome): Pathophysiological and Genetic Considerations
Endocr. Rev.,
October 1, 1998;
19(5):
521 - 539.
[Abstract]
[Full Text]
|
 |
|